Former Chairman of Global Research and Development and Chairman of Vaccines division at GSK

Moncef Slaoui, Ph.D., specializes in the research and development of vaccines and pharmaceuticals. In 2016, he was recognized as one of Fortune's "50 Greatest World Leaders" for his work in under-researched diseases common in the developing world.

Dr. Slaoui's career at GSK spanned 29 years, where he sat on its board of directors from May 2006 through March 2017. He was Chairman of Global Research and Development (R&D) from 2006 to 2014, where he led an overhaul of the company's pharmaceutical R&D and was also responsible for commercial pursuits such as new product launches and lifecycle management. Dr. Slaoui was also Chairman of GSK's vaccine division from 2009 until his retirement from the company in June 2017.

Early in his career, he was instrumental in the development of the vaccines Rotarix®, to prevent infantile rotavirus gastroenteritis; Synflorix®, to prevent pneumococcal disease; Cervarix®, to prevent cervical cancer; Mosquirix, to prevent Plasmodium Malaria disease; and Shingrix, to prevent Shingles.

After his retirement from GSK, Dr. Slaoui joined Medicxi Life Sciences as a partner. He also took on a number of independent board positions, including chairman of the board of Galvani, a bioelectronics-focused company jointly owned by GSK and Verily life sciences, and independent board director of Moderna, Sutrovax and Artizan Biotechnology.

Dr. Slaoui earned a Ph.D. in molecular biology and immunology from the Université Libre de Bruxelles in Belgium, completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine, Boston, and was a Professor of Immunology at the University of Mons, Belgium.